CBIZ 10-K/A Locks In Material Weaknesses, Adverse Auditor Opinion, and Segment Recast
CBZ has more than doubled off its 52-week low of $24.29.
Summary
CBIZ's amended 10-K formalizes two material weaknesses in internal controls with an adverse auditor opinion, recasts segment reporting, and discloses a voluntary rescission offer for improperly issued ESPP shares — all while a $5 billion acquisition is pending.
Key Events · Corporate Governance and Compliance · CBZ
-
Adverse Auditor Opinion on Internal Controls
KPMG issued an adverse opinion on CBIZ's internal control over financial reporting as of December 31, 2025, due to material weaknesses in ESPP administration and goodwill reassignment among reporting units.
-
Material Weaknesses Formalized
The two material weaknesses — related to the employee stock purchase plan and goodwill reassignment — are now formally documented in the amended 10-K, following their initial disclosure in the Q2 2026 10-Q filed yesterday.
-
ESPP Rescission Offer
CBIZ will offer to rescind up to 481,049 shares purchased under the ESPP between October 2023 and April 2026 because they exceeded the number of shares authorized and registered.
-
Segment Reporting Recast
The company recast its segment reporting from three to two segments — Financial Services and Benefits and Insurance Services — with retrospective adjustments to prior periods.
Analysis · CBZ · Trade & Services
This amendment to CBIZ's 2025 annual report elevates the previously disclosed material weaknesses by adding an adverse auditor opinion on internal controls — a notable escalation. It also recasts the business into two segments and reveals a voluntary rescission offer for nearly half a million shares improperly issued under the employee stock purchase plan. While the weaknesses were flagged in yesterday's 10-Q, this filing cements them in the audited 10-K and adds new details, including the auditor's formal adverse opinion and the ESPP rescission plan. The filing lands against the backdrop of a pending $5 billion all-cash acquisition by Grant Thornton at $55 per share, making any control deficiencies or restatements particularly sensitive.
At the time of this filing, CBZ was trading at $55.08 on NYSE in the Trade & Services sector, with a market capitalization of approximately $3B. The 52-week trading range was $24.29 to $67.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.